Close Menu

FDA

Visby's test is a fully integrated PCR device that detects SARS-CoV-2 RNA, while SNIBE's test comprises assays for two different antibodies against the virus.

The proposed order is intended to give patients more timely access to the tests by moving them from Class III to Class II and providing special controls.

The additions improve the system's performance and expand its antimicrobial susceptibility testing menu for bloodstream infections.

 

The test detects the presence of two biomarkers within a single cell associated with HPV infections that can progress to cervical cancer.

The test is designed to detect and differentiate SARS-CoV-2, influenza A, and influenza B and runs on the company's benchtop Cobas Liat system.

The agency is providing the material freely and asking for feedback, so it can fix possible problems before more widely disseminating it to labs and companies.

Comparing the BD and Quidel rapid antigen tests showed they performed similarly despite sensitivity differences in initial FDA filings.

The company received Emergency Use Authorization from the US Food and Drug Administration last month for a SARS-CoV-2 total antibody test.

The community is poised to be the primary channel for stakeholders to communicate PGx concerns with FDA, but it is unclear if all stakeholders will participate.

The BioCheck chemiluminescence tests can process human serum samples in 30 minutes to detect IgG and IgM antibodies.

Pages